MT1-MMP in breast cancer: induction of VEGF-C correlates with metastasis and poor prognosis

Cancer Cell International

Changsheng Ye²  Fan Gu²  Xiaolei Hu²  Lujia Chen²  Ping He¹  Guangyu Yao² 

[1] Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China;Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China

关键词: Breast cancer;    Metastasis;    Lymphangiogenesis;    Vascular endothelial growth factor-C;    Membrane-type matrix 1 metalloproteinases;   

Others  :  792814
DOI  :  10.1186/1475-2867-13-98

 received in 2013-05-12, accepted in 2013-10-08,  发布年份 2013

【 摘 要 】

Background

Recent evidence suggests that vascular endothelial growth factor-C (VEGF-C)- dependent tumour production promotes lymphangiogenesis, while membrane-type matrix 1 metalloproteinase (MT1-MMP) is involved in the critical steps leading to carcinogenesis. However, the role of MT1-MMP in lymphangiogenesis and lymphatic metastasis remains poorly understood. In the present study, we investigated the relationship between MT1-MMP and VEGF-C in human breast cancer and correlated MT1-MMP and VEGF-C expression with lymphangiogenesis and prognosis.

Methods

MT1-MMP and VEGF-C levels were compared in five breast carcinoma cell lines. We used a membrane invasion assay to assess the effect of MT1-MMP and VEGF-C expression, as well as anti-MT1-MMP and VEGF-C antibodies, on cancer cell invasion. We further assessed MT1-MMP and VEGF-C immunoreactivity and lymph vessels in a cohort of human breast cancer specimens (n = 106) and associated MT1-MMP and VEGF-C expression with clinicopathological parameters, such as lymphatic vessel density (LVD), and patient prognosis.

Results

MT1-MMP and VEGF-C expression differed among the five breast cancer cell lines and MT1-MMP and VEGF-C expression were correlated with tumour cell invasion. VEGF-C mRNA expression levels and invasive activity of MDA-MB-231 cells was inhibited by an anti-MT1-MMP antibody in a concentration-dependent manner. A significant correlation was found between the expression of MT1-MMP and VEGF-C in breast cancer patient samples and elevated MT1-MMP and VEGF-C expression was associated with higher LVD, lymph node metastasis, cancer stage, and a decline in overall survival rates.

Conclusions

Our data demonstrate that MT1-MMP expression is closely correlated with VEGF-C expression, and that MT1-MMP promotes lymphangiogenesis by up-regulating VEGF-C expression in human breast cancer. Thus, elevated MT1-MMP may serve as a significant prognostic factor in breast cancer.

【 授权许可】

   
2013 Yao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Genis L, Galvez BG, Gonzalo P, Arroyo AG: MT1-MMP: universal or particular player in angiogenesis? Cancer Metastasis Rev 2006, 25(1):77-86.
• [2]Itoh Y, Nagase H: Matrix metalloproteinases in cancer. Essays Biochem 2002, 38:21-36.
• [3]Zucker S, Pei D, Cao J, Lopez-Otin C: Membrane type-matrix metalloproteinases (MT-MMP). Curr Topics Dev Biol 2003, 54:1-74.
• [4]Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370(6484):61-65.
• [5]Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr: Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. Faseb J 1993, 7(15):1434-1441.
• [6]Sato H, Takino T, Miyamori H: Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 2005, 96(4):212-217.
• [7]Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7(2):192-198.
• [8]Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y, Sugimachi K: Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. British J Cancer 2000, 83(7):887-891.
• [9]Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ: A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 2006, 20(19):2673-2686.
• [10]Gilles C, Polette M, Coraux C, Tournier JM, Meneguzzi G, Munaut C, Volders L, Rousselle P, Birembaut P, Foidart JM: Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. J Cell Sci 2001, 114(Pt 16):2967-2976.
• [11]Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE, Brooks PC: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001, 154(5):1069-1079.
• [12]Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack MS, Friedl P: Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007, 9(8):893-904.
• [13]Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M: Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001, 153(5):893-904.
• [14]Suenaga N, Mori H, Itoh Y, Seiki M: CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene 2005, 24(5):859-868.
• [15]Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY: Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer 2000, 86(1):15-23.
• [16]Deryugina EI, Ratnikov BI, Postnova TI, Rozanov DV, Strongin AY: Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem 2002, 277(12):9749-9756.
• [17]Sodek KL, Ringuette MJ, Brown TJ: MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. British J Cancer 2007, 97(3):358-367.
• [18]Bonnomet A, Polette M, Strumane K, Gilles C, Dalstein V, Kileztky C, Berx G, van Roy F, Birembaut P, Nawrocki-Raby B: The E-cadherin-repressed hNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression. Oncogene 2008, 27(26):3692-3699.
• [19]Chernov AV, Sounni NE, Remacle AG, Strongin AY: Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem 2009, 284(19):12727-12734.
• [20]Achen MG, Stacker SA: Molecular control of lymphatic metastasis. Ann NY Acad Sci 2008, 1131:225-234.
• [21]Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al.: The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer cell 2006, 9(3):209-223.
• [22]Yu M, Tang Z, Alousi S, Berk RS, Miller F, Kosir MA: Expression patterns of lymphangiogenic and angiogenic factors in a model of breast ductal carcinoma in situ. Am J Surg 2007, 194(5):594-599.
• [23]Bock JM, Sinclair LL, Bedford NS, Jackson RE, Lee JH, Trask DK: Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck. Arch Otolaryngolog Head Neck Surg 2008, 134(4):355-362.
• [24]Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT, Bremnes RM: Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007, 13(22 Pt 1):6649-6657.
• [25]Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM: Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009, 4(5):578-585.
• [26]Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K, Hermanns MI, Kirkpatrick CJ: Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int J Oncol 2008, 32(3):585-592.
• [27]Witte D, Thomas A, Ali N, Carlson N, Younes M: Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002, 22(3):1463-1466.
• [28]Simiantonaki N, Taxeidis M, Jayasinghe C, Kirkpatrick CJ: Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status. Anticancer Res 2007, 27(5A):3245-3250.
• [29]Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo A, Burian M: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003, 25(6):464-474.
• [30]Warburton G, Nikitakis NG, Roberson P, Marinos NJ, Wu T, Sauk JJ Jr, Ord RA, Wahl SM: Histopathological and lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell carcinoma. J Oral Maxillofac Surg 2007, 65(3):475-484.
• [31]Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M: Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res 2005, 11(2 Pt 1):584-593.
• [32]Ma C, Lin H, Leonard SS, Shi X, Ye J, Luo J: Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro. Oncogene 2003, 22(34):5281-5290.
• [33]Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nature Rev 2003, 3(1):55-63.
• [34]Kim HJ, Park CI, Park BW, Lee HD, Jung WH: Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 2006, 47(3):333-342.
• [35]Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, Trudel D: The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006, 8(3):R28. BioMed Central Full Text
• [36]Ogura S, Ohdaira T, Hozumi Y, Omoto Y, Nagai H: Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk. J Surg Oncol 2007, 96(1):46-53.
• [37]Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mansel RE: Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 2006, 17(4):583-590.
• [38]Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999, 189(2):161-168.
• [39]Mylona E, Nomikos A, Magkou C, Kamberou M, Papassideri I, Keramopoulos A, Nakopoulou L: The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology 2007, 50(3):338-347.
• [40]Ishigaki S, Toi M, Ueno T, Matsumoto H, Muta M, Koike M, Seiki M: Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn J Cancer Res 1999, 90(5):516-522.
• [41]Teramoto S, Arihiro K, Koseki M, Kataoka T, Asahara T, Ohdan H: Role of vascular endothelial growth factor-C and -D mRNA in breast cancer. Hiroshima J Med Sci 2008, 57(2):73-78.
• [42]Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, et al.: Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 2003, 16(4):309-314.
• [43]Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S, Sonoo H: Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999, 90(9):977-981.
• [44]Li YS, Kaneko M, Amatya VJ, Takeshima Y, Arihiro K, Inai K: Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast. Pathol Int 2006, 56(5):256-261.
• [45]Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG: Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. British J Cancer 2007, 96(7):1092-1100.
• [46]Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K: Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001, 66(2):159-164.
• [47]Bando H, Weich HA, Horiguchi S, Funata N, Ogawa T, Toi M: The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases. Oncol Rep 2006, 15(3):653-659.
• [48]Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K: Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 2006, 12(4):1201-1207.
• [49]Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX, Wan L, Chen SY: Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC cancer 2008, 8:4. BioMed Central Full Text
• [50]Watanabe O, Kinoshita J, Shimizu T, Imamura H, Hirano A, Okabe T, Aiba M, Ogawa K: Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer. J Exp Clin Cancer Res 2005, 24(1):75-82.
• [51]Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, Birner P: VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 2006, 139(6):839-846.
• [52]Gisterek I, Matkowski R, Kozlak J, Dus D, Lacko A, Szelachowska J, Kornafel J: Evaluation of prognostic value of VEGF-C and VEGF-D in breast cancer–10 year’s follow-up analysis. Anticancer Res 2007, 27(4C):2797-2802.
• [53]van der Schaft DW, Pauwels P, Hulsmans S, Zimmermann M, van de Poll-Franse LV, Griffioen AW: Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer letters 2007, 254(1):128-136.
• [54]Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
• [55]Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, Schoppmann SF, Stingl G, Kerjaschki D, Maurer D: Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med 2001, 194(6):797-808.
• [56]Alitalo K, Tammela T, Petrova TV: Lymphangiogenesis in development and human disease. Nature 2005, 438(7070):946-953.
• [57]Boardman KC, Swartz MA: Interstitial flow as a guide for lymphangiogenesis. Circulation Res 2003, 92(7):801-808.
• [58]Bauer SM, Bauer RJ, Liu ZJ, Chen H, Goldstein L, Velazquez OC: Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. J Vasc Surg 2005, 41(4):699-707.
• [59]Nakamura ES, Koizumi K, Kobayashi M, Saiki I: Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. Cancer science 2004, 95(1):25-31.
• [60]Choi WW, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, Cohen C, Young AN: Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005, 18(1):143-152.
• [61]Kahn HJ, Marks A: A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002, 82(9):1255-1257.
• [62]Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995, 36(2):169-180.